Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,134 shares of the biotechnology company’s stock after selling 872 shares during the period. Mutual of America Capital Management LLC’s holdings in Bio-Techne were worth $1,631,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TECH. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bio-Techne in the 3rd quarter valued at $27,000. Harbour Investments Inc. grew its position in Bio-Techne by 305.0% during the 4th quarter. Harbour Investments Inc. now owns 324 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 244 shares during the last quarter. Resurgent Financial Advisors LLC acquired a new position in Bio-Techne in the fourth quarter valued at $29,000. CVA Family Office LLC purchased a new stake in shares of Bio-Techne in the fourth quarter valued at about $31,000. Finally, Lazard Asset Management LLC boosted its stake in shares of Bio-Techne by 447.5% during the fourth quarter. Lazard Asset Management LLC now owns 553 shares of the biotechnology company’s stock worth $45,000 after buying an additional 452 shares during the period. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Insider Transactions at Bio-Techne

In other Bio-Techne news, Director Roeland Nusse sold 10,400 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $76.98, for a total transaction of $800,592.00. Following the completion of the transaction, the director now directly owns 43,097 shares in the company, valued at approximately $3,317,607.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.45% of the company’s stock.

Bio-Techne Trading Down 0.1 %

Shares of Bio-Techne stock opened at $62.12 on Monday. The company has a 50-day moving average of $70.50 and a two-hundred day moving average of $68.65. Bio-Techne Co. has a 12-month low of $51.79 and a 12-month high of $89.91. The company has a current ratio of 4.37, a quick ratio of 3.03 and a debt-to-equity ratio of 0.23. The stock has a market cap of $9.76 billion, a PE ratio of 45.01, a price-to-earnings-growth ratio of 7.04 and a beta of 1.22.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Thursday, February 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.03). The firm had revenue of $272.60 million during the quarter, compared to analysts’ expectations of $277.48 million. Bio-Techne had a net margin of 19.58% and a return on equity of 14.21%. On average, research analysts anticipate that Bio-Techne Co. will post 1.52 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Monday, February 12th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.52%. The ex-dividend date was Friday, February 9th. Bio-Techne’s dividend payout ratio (DPR) is presently 23.19%.

Analyst Ratings Changes

Several equities analysts recently issued reports on TECH shares. Stephens dropped their price target on Bio-Techne from $92.00 to $87.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Royal Bank of Canada decreased their price target on Bio-Techne from $85.00 to $75.00 and set a “sector perform” rating for the company in a report on Friday, February 2nd. Scotiabank began coverage on shares of Bio-Techne in a research report on Thursday, February 8th. They issued a “sector outperform” rating and a $80.00 price objective on the stock. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Stifel Nicolaus downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $83.90.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.